Table 4.
Effects of resveratrol on cardiac dysfunction and heart rate in anesthetized DM mice (6 months).
| Group | HR (beats/min) | LVID (mm) | IVS (mm) | LVPW (mm) | % EF (%) | % FS (%) |
|---|---|---|---|---|---|---|
| Control | 483 ± 27 | 3.6 ± 0.19 | 0.76 ± 0.04 | 0.85 ± 0.09 | 89.35 ± 3.70 | 60.10 ± 4.86 |
| Resveratrol | 478 ± 21 | 3.58 ± 0.12 | 0.78 ± 0.02 | 0.92 ± 0.03 | 88.24 ± 4.52 | 56.25 ± 4.73 |
| DM | 464 ± 23 | 3.99 ± 0.12∗ | 0.99 ± 0.02∗ | 1.05 ± 0.02∗ | 66.25 ± 3.25∗ | 36.00 ± 3.63∗ |
| DM/resveratrol | 468 ± 17 | 3.76 ± 0.14# | 0.83 ± 0.02# | 0.90 ± 0.02# | 80.05 ± 3.60# | 48.22 ± 4.50# |
Data are presented as means ± SEM. LVID = LV end-diastolic diameter; LVPW = LV posterior wall; IVS = interventricular septum; FS = fractional shortening; EF = ejection fraction. ∗p < 0.05 versus control. #p < 0.05 versus DM group.